Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis

Janis L. Abkowitz, Gerard Schaison, Farid Boulad, Deborah L. Brown, George R. Buchanan, Christine A. Johnson, Jeffrey C. Murray, and Kathleen M. Sabo

A 47-year-old woman with severe macrocytic anemia markedly improved during the second and third trimesters of 3 pregnancies and when breast-feeding her 2 children. Because the serum prolactin level is elevated at these times, we later treated her with metoclopramide (10 mg orally 3 times daily), a medication known to induce prolactin release. Her serum prolactin levels increased from 7 to 133 ng/mL (normal < 20 ng/mL) and hematocrit from 17% to 22% to 35%. With continued therapy (now 10 mg orally daily), her hematocrit has ranged from 30% to 40% for 6 years, although the macrocytosis persists (mean corpuscular volume, 100-112 fL). On the basis of this observation, a pilot study was undertaken of metoclopramide therapy in patients with Diamond-Blackfan anemia who were refractory to low doses of corticosteroids. Fifteen patients were enrolled and 9 completed the planned 16 weeks of therapy. Three individuals responded, suggesting that this therapeutic approach may benefit others.

As with the index case, the anemia did not improve until 12 to 15 weeks of therapy had been completed. (Blood. 2002;100:2687-2691)

Introduction

Diamond-Blackfan anemia is a congenital macrocytic anemia, characterized by a low reticulocyte count, the absence or severe reduction of hemoglobin (Hgb)—containing cells in the marrow, and normal megakaryocytic and granulocytic differentiation.1-2 Approximately 30% of patients have physical anomalies, including short stature and craniofacial, neck, and thumb malformations.2-5 Ten percent have a family history of anemia, generally with a dominant inheritance pattern. The genetic basis of Diamond-Blackfan anemia is likely heterogeneous. Abnormalities of the gene encoding ribosomal protein S19 (localized to chromosome 19q13.2) have been reported in 25% of families (as well as 25% of sporadic cases),6-8 whereas linkage to different chromosomes has been implicated in other families.5,7,9,10 Although the anemia may initially respond to corticosteroid therapy, many patients require life-long red blood cell (RBC) transfusions, leading to infectious complications and iron overload.2-5 Other therapies include androgens, cyclosporine, and interleukin 3 (IL-3), which appear to be efficacious in 10% to 15% of patients,2-5,11-13 and marrow transplantation.14-16 Spontaneous remissions, especially during adolescence, have been reported.5

Our observations in a unique patient suggest that metoclopramide may also be an effective therapy. The patient’s severe macrocytic anemia remitted during each of 3 pregnancies and when breast-feeding her 2 children, times when the serum prolactin level is elevated.15 Thus, when she finished childbearing and was again symptomatically anemic (hematocrit [Hct], 17%-22%), we treated her with metoclopramide, which is known to induce the release of prolactin from the pituitary.16-21 The Hct slowly increased and she has remained asymptomatic and transfusion independent (Hct, 30%-40%, mean corpuscular volume [MCV], 100-112 fL) for 6 years. The mechanism by which prolactin might affect erythropoiesis was investigated, and a small pilot study was undertaken to determine if metoclopramide could be effective in patients with Diamond-Blackfan anemia.

Patient, materials, and methods

Index case history

At age 14 years, the index patient received iron for a “very low blood count.” At age 21 years, the patient was a competitive athlete (cross-country skier), yet Hct values of 17% and 19% were obtained when she volunteered as a healthy control for a research study. At age 25 years, Hct values were 27% to 33%, MCV was 107 to 123 fL, and reticulocytes were 0.6% to 1.1%.

At age 33, during the initial 8 weeks of her first pregnancy, Hct values were 16% to 18% (MCV, 119-122; reticulocytes, 0.3%; Figure 1A). The marrow had diminished erythropoiesis (marrow/erythroid [M/E] > 25:1), normal granulocytic and megakaryocytic differentiation, and a normal karyotype. Although the pregnancy ended with a stillbirth at week 30, by week 25, the patient’s Hct spontaneously increased to 31% to 33%. A computed tomography scan of the chest excluded thymoma.

When next pregnant, the patient was received transfusions to maintain her Hct over 25% (Figure 1B). At 15 weeks (3 weeks after her last RBC transfusion) she was evaluated at the University of Washington Medical Center. The Hct was 26%, reticulocytes were 3.2%, and the remainder of the complete blood count was normal. The marrow aspirate (M/E = 4:1) had left-shifted erythropoiesis and a normal karyotype. The B12, folate, and ...
A serum prolactin level was measured prior to the administration of metoclopramide and was 7 ng/mL (normal < 20 ng/mL). With metoclopramide 10 mg thrice and twice daily, serum levels ranged from 42 to 133 ng/mL (Figure 2). When the patient’s metoclopramide dose was 10 mg daily, a serum prolactin level (obtained 8 hours after the ingestion of medication) was 5 ng/mL. Five years after beginning metoclopramide, the kinetics of the prolactin response was studied quantitatively and was similar to that reported in pharmacologic studies.17-20 The baseline serum prolactin level was 3 ng/mL. Two hours after ingestion of 10 mg metoclopramide, prolactin was measured at 140 ng/mL.

Marrow culture studies

Marrow cells were obtained from the posterior iliac crest of the index patient and healthy volunteers (after informed consent, as approved by the University of Washington Institutional Review Board [IRB]). MMNCs were separated by centrifugation with a density gradient (1.077 g/mL; LSM, Cappel, Aurora, OH) and were cultured in 1.4% methylcellulose (Dow Chemicals, Costa Mesa, PA) (105 cells/mL) in the presence of 30% heat-inactivated fetal bovine serum (Summit Biotechnology, Fort Collins, CO), 1 U/mL recombinant human (rh) erythropoietin (Epo) (3 U/mL; rhIL-3 (Genzyme Diagnostics, Cambridge, MA), and 100 ng/mL rh stem cell factor (rhSCF; a gift from Amgen, Thousand Oaks, CA). In some experiments, rh prolactin (R & D Systems, Minneapolis, MN) was added or lower cytokine concentrations (ie, 0.2 U/mL Epo). Erythroid bursts (> 200 erythroid cells) and granulocyte-macrophage colonies (> 50 granulocytic or monocytic cells) were quantitated after 14 days of incubation at 37°C, 5% CO2/95% air. Erythroid colonies (8-50 erythroid cells) were enumerated at day 7.

To determine if prolactin receptors were present on hematopoietic progenitor cells, MMNCs were incubated with monoclonal antibody to the prolactin receptor (clone U5; Affinity Bioreagents, Golden, CO; concentration 2.8-6 µg/106 cells or 19-120 µg/mL, 30 minutes, 4°C), and then with

Marrow culture studies

Marrow cells were obtained from the posterior iliac crest of the index patient and healthy volunteers (after informed consent, as approved by the University of Washington Institutional Review Board [IRB]). MMNCs were separated by centrifugation with a density gradient (1.077 g/mL; LSM, Cappel, Aurora, OH) and were cultured in 1.4% methylcellulose (Dow Chemicals, Costa Mesa, PA) (105 cells/mL) in the presence of 30% heat-inactivated fetal bovine serum (Summit Biotechnology, Fort Collins, CO), 1 U/mL recombinant human (rh) erythropoietin (Epo) (3 U/mL; rhIL-3 (Genzyme Diagnostics, Cambridge, MA), and 100 ng/mL rh stem cell factor (rhSCF; a gift from Amgen, Thousand Oaks, CA). In some experiments, rh prolactin (R & D Systems, Minneapolis, MN) was added or lower cytokine concentrations (ie, 0.2 U/mL Epo). Erythroid bursts (> 200 erythroid cells) and granulocyte-macrophage colonies (> 50 granulocytic or monocytic cells) were quantitated after 14 days of incubation at 37°C, 5% CO2/95% air. Erythroid colonies (8-50 erythroid cells) were enumerated at day 7.

To determine if prolactin receptors were present on hematopoietic progenitor cells, MMNCs were incubated with monoclonal antibody to the prolactin receptor (clone U5; Affinity Bioreagents, Golden, CO; concentration 2.8-6 µg/106 cells or 19-120 µg/mL, 30 minutes, 4°C), and then with

Serum prolactin levels in the index patient

A serum prolactin level was measured prior to the administration of metoclopramide and was 7 ng/mL (normal < 20 ng/mL). With metoclopramide 10 mg thrice and twice daily, serum levels ranged from 42 to 133 ng/mL (Figure 2). When the patient’s metoclopramide dose was 10 mg daily, a serum prolactin level (obtained 8 hours after the ingestion of medication) was 5 ng/mL. Five years after beginning metoclopramide, the kinetics of the prolactin response was studied quantitatively and was similar to that reported in pharmacologic studies.17-20 The baseline serum prolactin level was 3 ng/mL. Two hours after ingestion of 10 mg metoclopramide, prolactin was measured at 140 ng/mL.

Marrow culture studies

Marrow cells were obtained from the posterior iliac crest of the index patient and healthy volunteers (after informed consent, as approved by the University of Washington Institutional Review Board [IRB]). MMNCs were separated by centrifugation with a density gradient (1.077 g/mL; LSM, Cappel, Aurora, OH) and were cultured in 1.4% methylcellulose (Dow Chemicals, Costa Mesa, PA) (105 cells/mL) in the presence of 30% heat-inactivated fetal bovine serum (Summit Biotechnology, Fort Collins, CO), 1 U/mL recombinant human (rh) erythropoietin (Epo) (3 U/mL; rhIL-3 (Genzyme Diagnostics, Cambridge, MA), and 100 ng/mL rh stem cell factor (rhSCF; a gift from Amgen, Thousand Oaks, CA). In some experiments, rh prolactin (R & D Systems, Minneapolis, MN) was added or lower cytokine concentrations (ie, 0.2 U/mL Epo). Erythroid bursts (> 200 erythroid cells) and granulocyte-macrophage colonies (> 50 granulocytic or monocytic cells) were quantitated after 14 days of incubation at 37°C, 5% CO2/95% air. Erythroid colonies (8-50 erythroid cells) were enumerated at day 7.

To determine if prolactin receptors were present on hematopoietic progenitor cells, MMNCs were incubated with monoclonal antibody to the prolactin receptor (clone U5; Affinity Bioreagents, Golden, CO; concentration 2.8-6 µg/106 cells or 19-120 µg/mL, 30 minutes, 4°C), and then with
Patients with a clinical diagnosis of Diamond-Blackfan anemia received metoclopramide for 16 weeks at a standard dose for gastrointestinal reflux (eg, 10 mg orally 2-3 times daily for adults). Patients who required transfusions or who were dependent on high-dose corticosteroid therapy were eligible for this trial. Hgb, Hct, and serum prolactin levels were obtained prior to metoclopramide therapy and at weeks 8, 12, and 16. Transfusion intervals were noted. Although the intent was to maintain other medications (ie, prednisone) at baseline doses, these drugs could be adjusted at the discretion of the patient’s physician. Each physician obtained IRB or equivalent institutional approval and served as the principal investigator for the local study. Response at 16 weeks (the duration of study), was defined as: (1) a 30% increase in Hct (or Hgb) or (2) a stable or improved Hct (or Hgb) and a 50% or greater increase in the transfusion interval or 50% or greater reduction in the prednisone dose. Because the index patient did not meet the criteria for response until 15 weeks (Figure 2), only patients completing the entire 16-week course of study were considered evaluable.

Role of prolactin in erythroid differentiation

The prolactin receptor, a type 1 cytokine receptor, is structurally similar to receptors for IL-1 through IL-7, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), Epo, and growth hormone.22 Prolactin and growth hormone (which is able to bind to the prolactin receptor23) have been implicated in erythropoiesis.24-29 Whether this role is direct (mediated by the binding of hormone to a receptor on erythroid progenitor cells) or indirect (mediated through effects on nonerythroid cells within the marrow microenvironment) is uncertain.24-28,30 Thus, in vitro studies were undertaken. The addition of rh prolactin (10-500 ng/mL) to cultures of marrow cells from the index patient or control individuals (n = 3) had no effect on the numbers of detectable BFU-Es (data not shown). The addition of exogenous prolactin also failed to improve erythroid

Table 1. Patients with Diamond-Blackfan anemia treated for 16 weeks with metoclopramide

Patient no. | Sex | Age at study, y | Age at diagnosis | Anomalies | Prior therapy | Treatment at initiation of study | Response | Highest prolactin level (ng/mL) on metoclopramide
--- | --- | --- | --- | --- | --- | --- | --- | ---
1 | M | 32 | 4 | Turner-like, plebalism, short stature | — | P, Tx | Y | 30
2 | F | 20 | 1 | Turner-like, short stature | P, C, IL-3 | Tx | Y | 142
3 | M | 3 | 16 | None | Tx | P | Y | 204
4 | M | 23 | 3 | Hypoplasia, short stature | A, P, IL-3 | Tx | N | 33
5 | M | 9 | 11 | None | P | Tx | N | 92
6 | M | 4 | 2 | None | P | Tx | N | 21
7 | M | 10 | 4 | Short stature | — | P | N | 15
8 | M | 30 | 7 | None | A, P | Tx | N | 20
9 | M | 17 | 1 | Widespread eyes, short stature | A, P, C, IL-3 | Tx | N | 31

Prolactin levels were 2-16 ng/mL (normal, < 20 ng/mL) in patients prior to metoclopramide administration. Responding patients are listed as patients 1, 2, and 3. Although anemia was noted after the first year of his life, Diamond-Blackfan anemia was diagnosed in patient 1 at age 4 years (Hgb, 7.2 g/dL; MCV, 101 fL; marrow demonstrated 4% of RBC precursors). Subsequent testing showed no mutation in the coding sequence of RPS19. At the time of metoclopramide administration, the patient was 32 years old and received prednisone 20 mg daily and RBC transfusions each 5 to 6 weeks. At 16 weeks (the duration of this study), his Hct was 29% (Hgb, 9.9 g/dL). At 6 months with continued therapy, his Hct was 36% (Hgb, 12.2 g/dL). With a prednisone taper, the Hgb decreased to 7.3 g/dL. Prednisone (20 mg daily) was restarted and the Hgb remains more than 12 g/dL for 16 months. He currently takes 10 mg metoclopramide twice a day. Diamond-Blackfan anemia was diagnosed in patient 2 when she was 1 year old (Hct, 21%; MCV, 94 fL; 9% of nucleated marrow cells were RBC precursors). Subsequent studies showed a normal HgbF and no abnormality in the coding sequence of RPS19. She initially responded to steroids (1971-1978), required no therapies between 1980 and 1990 (adolescence), but relapsed in 1990 with steroid-resistant disease. She then failed trials of IL-3 and cyclosporine and required RBC transfusions every 5 weeks. Her Hct (obtained 7 days after transfusion) was 22% and hemoglobin was 7.5 g/dL. After 14 weeks of metoclopramide therapy, her transfusion interval increased, meeting response criteria. At 7 months of therapy, she became transfusion independent (Hgb, 10 g/dL). The Hgb has remained more than 9 g/dL for 2 years (on metoclopramide 20 mg daily). Patient 3 (3-year-old boy) has been steroid dependent since his diagnosis at age 16 months. At that time, his Hct was 15.3%, MCV 103 fL, marrow had 7% erythroid precursors, and ADAM was elevated at 1.57, and HgbF was 19.9%. RPS19 status is uncertain. At the time of study, he required daily prednisone at a dose of 5 mg alternating with 10 mg to maintain the Hgb at 6.8 g/dL. After 12 weeks of metoclopramide (0.2 mg/kg 3 times a day), his Hgb was 9.6 g/dL, meeting response criteria. At 16 weeks, the Hgb was 9.9 g/dL and the prednisone dose was tapered to 5 mg daily, then 5 mg alternating with 2 mg daily (Hgb values, 8.4-8.9 g/dL). When the metoclopramide dose was decreased to once a day (at 9 months), the Hgb fell to 6.7 g/dL, but recovered after restarting the 3-times-a-day dose. Because serum prolactin levels were measured at unknown times relative to 3-times-a-day metoclopramide ingestion, it is unlikely that values reflect peak responses. Three patients (ages 12, 21, and 30) discontinued therapy at weeks 12, 12, and 12, respectively because of toxicity (fatigue). Three patients (ages 4, 12, and 16) were noncompliant and removed from the study at weeks 9, 8, and 3. Their presentations and clinical characteristics were similar to evaluable patients.

A indicates androgens; P, prednisone or methylprednisolone; C, cyclosporine; Tx, RBC transfusions.
diﬀerentiation when cytokine supplementation was suboptimal. When marrow cells (n = 5 independent experiments) were sorted by ﬂuorescence-activated cell sorting (FACS) for the presence or absence of prolactin receptors, 94% ± 3% of BFU-Es, 100% of CFU-Es, and 96 ± 2% of granulocyte-macrophage colony-forming units (CFU-GMs) were in the prolactin receptor-negative fraction. These data suggest that the eﬀects of prolactin on erythropoiesis are indirect.

Discussion

Diamond-Blackfan anemia is a clinically, as well as genetically, heterogeneous disorder. Family members with deﬁcits in the coding sequence of ribosomal protein S19 may have normal Hct values,31,32 suggesting that cofactors must modulate disease phenotype.31 Also, although 95% of patients with Diamond-Blackfan anemia are diagnosed by age 7 years, the disease has been diagnosed in adults, including elderly persons.33

The index patient for this study had a persistent macrocytic anemia, low reticulocyte count, normal granulocyte and platelet production, a paucity of erythroid cells in the marrow aspirate, normal marrow cytogenetics, an elevated number of RBCs containing HgbF, normal erythrocyte adenosine deaminase (ADA), no congenital anomalies, and no evidence of progression to aplastic anemia or leukemia. Her clinical course was particularly instructive, because her anemia remitted in the mid to late second trimester of 3 pregnancies and when she breast-fed her 2 children. Prolactin uniquely increases in pregnancy, and remains elevated, at least intermittently, with breast-feeding, because sucking induces prolactin release.15 Prolactin has been implicated in the support of erythropoiesis in vitro26,29 and in vivo.25,26,34 Case reports from the 1970s suggest that bovine prolactin, administered intramuscularly (600-900 μg/kg/d) may improve anemia in patients.35 In these individuals both iron clearance from serum and iron utilization in RBC production were increased.35

For these reasons, the patient received metoclopramide, a dopamine antagonist that induces prolactin release. Metoclopramide has been both used in diagnostic studies of pituitary function,16-19 and administered chronically.20,21 Our patient received metoclopramide at a time that her Hct was 17% to 22% and had a dramatic response (Figure 2). Because a normal Hct was received metoclopramide at a time that her Hct was 17% to 22% and the 16-week course (Table 1), with 3 having clinically signiﬁcant responses. With continued therapy the Hgb further increased to 12.2 and 10 g/dL at 6 to 7 months in patients 1 and 2, respectively. The Hgb in patient 3 reached 9.9 g/dL at 16 weeks, and remained suﬃciently high (8.4-8.9 g/dL) to allow the subsequent taper of his prednisone dose. Thus, the anemia improved late, not until 12 to 15 weeks after the initiation of metoclopramide therapy, and continued to improve after the study formally ended, a pattern of response similar to that observed in the index patient.

Several factors may have contributed to the lack of metoclopramide response in the 6 other patients. Patients 7 and 8, as examples, had serum ferritin concentrations of 4400 and 4521 ng/mL, respectively, and clinical evidence of pituitary dysfunction. Also, prolactin release in response to metoclopramide is greater in women than men17 and in older than younger individuals.36 Men and younger individuals were disproportionately represented among study patients (Table 1). Recombinant human prolactin (when available) might be an appropriate therapeutic agent for individuals in whom the serum prolactin remains low, as well as those who experience fatigue or other complications while taking metoclopramide.

In the in vitro experiments, exogenous prolactin did not improve BFU-E diﬀerentiation, consistent with some,24 but in contrast to other,28 earlier studies. Prolactin receptors were not present on erythroid progenitor cells, suggesting that the action of prolactin on erythroid diﬀerentiation is indirect, potentially mediated by microenvironmental cells,29 such as T cells and monocytes, cells that express prolactin receptors29,30 and that produce cytokines known to aﬀect erythropoiesis, such as IL-3, insulinlike growth factor 1, and kit ligand (SCF). That the transient elevations in serum prolactin induced by metoclopramide can lead to improved erythropoiesis is also consistent with a paracrine mechanism.

When the index patient’s anemia improved during her pregnancies, with breast-feeding, and when taking metoclopramide, the MCV remained elevated. This suggests that metoclopramide improved erythropoiesis without correcting the underlying erythropoietic defect. Thus, it is possible that metoclopramide could beneﬁt patients with other refractory macrocytic anemias, such as myelodysplasia.

Acknowledgments

The authors would like to thank Drs Joseph Sack, Nancy Klein, Carl Kjoebech, Nancy Kernan, and Richard Minogue for their help in the clinical evaluation of the index and other patients, Dr Bert Glader for determining the erythrocyte ADA level, Dr Thalia Papayannopoulou for determining the percentage of red cells containing fetal hemoglobin, Dr Sandra Catlin for help with the statistical analysis, and Allan Dimanuahen and Zenaida Sisk for their help in the preparation of the manuscript.

References


Diamond-Blackfan anemia patients. DBA group of Societe d’Hematologie et d’Immunologie Pediatrique (SHIP), Gesellschaft fur Padiatri sche Onkologie und Hamburgologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPH). Pediatr Res. 1999;46:553-561.
Erratum

In the article by Molnines et al entitled “Essential role of the C5a receptor in E coli–induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation,” which appeared in the September 1, 2002, issue of Blood (Volume 100:1869-1877), the abstract’s fifth sentence should read, “Granulocyte and monocyte oxidative burst was complement dependent as it was reduced by 85% and 70%, respectively, by the C3 binding peptide compstatin.”
Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis

Janis L. Abkowitz, Gerard Schaison, Farid Boulad, Deborah L. Brown, George R. Buchanan, Christine A. Johnson, Jeffrey C. Murray and Kathleen M. Sabo